These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24341887)

  • 21. Dendritic cells as vectors for immunotherapy of cancer.
    Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
    Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses.
    Sabel MS
    Cryobiology; 2009 Feb; 58(1):1-11. PubMed ID: 19007768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cryoablation and immunotherapy of cancer.
    Yakkala C; Denys A; Kandalaft L; Duran R
    Curr Opin Biotechnol; 2020 Oct; 65():60-64. PubMed ID: 32088576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percutaneous comprehensive cryoablation for metastatic esophageal cancer after failure of radical surgery.
    Jiongyuan X; Lizhi N; Feng M; Shupeng L; Yin L; Mengtian L; Jianying Z; Fei Y; Jibing C; Jialiang L; Kecheng X
    Cryobiology; 2013 Dec; 67(3):363-8. PubMed ID: 24383130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy.
    Regen-Tuero HC; Ward RC; Sikov WM; Littrup PJ
    Radiol Imaging Cancer; 2021 Mar; 3(2):e200134. PubMed ID: 33817653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes.
    Takada M; Toi M
    Int J Clin Oncol; 2019 Jun; 24(6):608-613. PubMed ID: 30982153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunologic response to cryoablation of breast cancer.
    Sabel MS; Nehs MA; Su G; Lowler KP; Ferrara JL; Chang AE
    Breast Cancer Res Treat; 2005 Mar; 90(1):97-104. PubMed ID: 15770533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer vaccines.
    Pardoll DM
    Immunol Today; 1993 Jun; 14(6):310-6. PubMed ID: 8397772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the use of cryoablation and immunotherapy for breast cancer.
    Olagunju A; Forsman T; Ward RC
    Front Immunol; 2022; 13():1026475. PubMed ID: 36389815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of vaccines against self-antigens: the p53 paradigm.
    Chada S; Mhashilkar A; Roth JA; Gabrilovich D
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):169-73. PubMed ID: 12669451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour immunotherapy: the adjuvant treatment of the 21st century?
    Bremers AJ; Kuppen PJ; Parmiani G
    Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.
    Gribben JG; Ryan DP; Boyajian R; Urban RG; Hedley ML; Beach K; Nealon P; Matulonis U; Campos S; Gilligan TD; Richardson PG; Marshall B; Neuberg D; Nadler LM
    Clin Cancer Res; 2005 Jun; 11(12):4430-6. PubMed ID: 15958627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.
    Cerullo V; Koski A; Vähä-Koskela M; Hemminki A
    Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.